Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1

Nature Medicine

Volumn 6, Issue 1, 2000, Pages 41-48

  Jiménez, Benilde ^a,c   Volpert, Olga V ^a   Crawford, Susan E ^a   Febbraio, Maria ^b   Silverstein, Roy L ^b   Bouck, Noël ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CASPASE; MITOGEN ACTIVATED PROTEIN KINASE; THROMBOSPONDIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANGIOSTATINS; ANIMALS; ANTIGENS, CD36; APOPTOSIS; CASPASES; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MICROCIRCULATION; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; PLASMINOGEN; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-FYN; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1;

ANIMALIA;

EID: 0342445431     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/71517     Document Type: Article

References (48)

1. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
2. Bouck, N , Stellmach, V. & Hsu, S. How tumors become angiogenic. Adv. Cancer Res. 69, 135-174 (1996).
3. Volpert, O.V., Lawler, J. & Bouck, N.P. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc. Natl. Acad. Sci. USA 95, 6343-6348 (1998)
4. O'Reilly, M.S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328 (1994).
5. O'Reilly, M.S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997).
6. Boehm, T., Folkman, J., Browder, T. & O'Reilly, M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407 (1997).
7. Guo, N., Krutzsch, H.C., Inman, J.K. & Roberts, D.D. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 57, 1735-1742 (1997).
8. Claesson-Welsh, L. et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. Sci. USA 95, 5579-5583 (1998).
9. Lucas, R. et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92, 4730-4741 (1998).
10. Dhanabal. M. et al. Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 274, 11721-11726 (1999).
11. Yue, T.L. et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol. Pharmacol. 51, 951-962 (1992).
12. DiPietro, L.A. in Regulation of Angiogenesis (eds. Goldberg. I.D. & Rosen, E.M.) 295-313 (Birkhauser Verlag, Basel, Switzerland, 1997).
13. Roberts, D.D. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J. 10, 1183-1191 (1996).
14. Dawson, D.W. & Bouck, N. in Antiangiogenic Agents in Cancer (ed. Teicher, B.A.) 185-204 (Humana, Totowa, New Jersey, 1998).
15. Crawford, S.E. et al. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 93, 1159-1170 (1998).
16. Weinstat-Saslow, D.L. et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 54, 6504-6511 (1994).
17. Castle, V.P., Dixit, V.M. & Polverini, P.J. Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells. Lab. Invest. 77, 51-61 (1997).
18. Bleuel, K., Popp, S., Fusenig, N.E., Stanbridge, E.J. & Boukamp, P. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc. Natl. Acad. Sci. USA 96, 2065-2070 (1999).
19. Volpert, O.V. et al. Inhibition of angiogenesis by thrombospondin-2. Biochem. Biophys. Res. Comm. 217, 326-332 (1995).
20. Dawson, D.W. et al. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138, 707-717 (1997).
21. Huang, M.M., Bolen, J.B., Barnwell, J.W., Shattil, S.J. & Brugge, J.S. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc. Natl. Acad. Sci. USA 88, 7844-7848 (1991).
22. Bull, H.A., Brickell, P.M. & Dowd, P.M Src-related protein tyrosine kinases are physically associated with the surface antigen CD36 in human dermal microvascular endothelial cells. FEBS Lett. 351, 41-44 (1994).
23. Tolsma, S.S. et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol. 122, 497-511 (1993).
24. Cosulich, S. & Clarke, P. Apoptosis: does stress kill?. Curr. Biol. 6, 1586-1588 (1996).
25. Le-Niculescu, H. et al. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell. Biol. 19, 751-763 (1999).
26. Verheij, M. et al. Requirement for ceramide-initiated SAPK/JNK signaling in stress-induced apoptosis. Nature 380, 75-79 (1996).
27. Ichijo, H. et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275, 90-94 (1997).
28. Kumar, S. et al. Activation of the HIV-1 long terminal repeat by cytokines and environmental stress requires an active CSBP/p38 MAP kinase. J. Biol. Chem. 271, 30864-30869 (1996).
29. Polverini, P.J., Bouck, N.P. & Rastinejad, F. Assay and purification of naturally occurring inhibitor of angiogenesis. Meth. Enzymol. 198, 440-450 (1991).
30. Schultz-Cherry, S. & Murphy-Ullrich, J.E. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism . J. Cell Biol. 122, 923-932 (1993).
31. Storgard, C.M. et al. Decreased angiogenesis and arthritic disease in rabbits treated with an ανβ3 antagonist. J. Clin. Invest. 103, 47-54 (1999).
32. Jacobson, M.D., Weil, M. & Raff, M.C. Programmed cell death in animal development. Cell 88, 347-354 (1997).
33. Dragovich, T., Rudin, C.M. & Thompson, C.B. Signal transduction pathways that regulate cell survival and cell death. Oncogene 17, 3207-3213 (1998).
34. Nor, J.E., Christensen, J., Mooney, D.J. & Polverini, P.J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J. Pathol. 154, 375-384 (1999).
35. Benjamin, L.E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159-165 (1999).
36. Gupta, K. et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp. Cell Res. 247, 495-504 (1999).
37. Erpel, T. & Courtneidge, S.A. Src family protein tyrosine kinases and cellular signal transduction pathways. Curr. Opin. Cell Biol. 7, 176-182 (1995).
38. Miyakawa, T. et al. Fyn-kinase as a determinant of ethanol sensitivity: relation to NMDA-receptor function. Science 278, 698-701 (1997).
39. Grant, S.G.N. et al. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science 258, 1903-1910 (1992).
40. Juo, P., et al. Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Mol. Cell. Biol. 17, 24-35 (1997).
41. Cardone, M.H., Salvesen, G.S., Widmann, C., Johnson, G. & Frisch, S.M. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell 90, 315-323 (1997).
42. Kothakota, S. et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 278, 294-298 (1997).
43. Salazar, R., Bell, S.E. & Davis, G. E. Coordinate induction of the actin cytoskeletal regulatory proteins gelsolin, vasodilator-stimulated phosphoprotein, and profilin during capillary morphogenesis in vitro. Exp. Cell Res. 249, 22-32 (1999).
44. Brooks, P.C. et al. Integrin alphaV beta3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164 (1994).
45. Stromblad, S., Becker, J.C., Yebra, M., Brooks, P.C. & Cheresh, D.A. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J. Clin. Invest. 98, 426-433 (1996).
46. Streilein, J.W. Unraveling immune privilege. Science 270, 1158-1159 (1995).
47. Schlaepfer, D.D. & Hunter, T. Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases. Mol. Cell. Biol. 16, 5623-5633 (1996).
48. Febbraio, M., Abumrad, N.A., Haijar, D.P., Sharma, K., Pearce, S.F.A. & Silverstein, R.L. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 274, 19055-19062 (1999).